1. Home
  2. About FDA
  3. FDA Organization
  4. Office of the Commissioner
  5. Office of Policy, Legislation, and International Affairs
  6. Office of Global Policy and Strategy
  7. Office of Global Policy and Strategy Leadership
  1. Office of Global Policy and Strategy

Office of Global Policy and Strategy Leadership

Associate Commissioner for Global Policy and Strategy

Mark Adboo

Mark Abdoo is the Associate Commissioner for Global Policy and Strategy, providing executive oversight, strategic leadership and policy direction to FDA’s global policy, operations, trade, and diplomacy activities.

Mr. Abdoo joined the FDA in 2013 as the inaugural director of the Office of Public Health and Trade. In 2015, he took up the role of Associate Commissioner for Regulatory Policy, and in 2017 became Deputy Commissioner for Global Regulatory Operations and Policy (acting). 

Prior to his tenure at the FDA, Mr. Abdoo served in other senior positions in the Federal government including Senior Advisor in the Bureau for Food Security at the U.S. Agency for International Development, Director for Global Health and Food Security at the National Security Council, and in various senior positions in what was then the Office of Global Health Affairs in the Office of the Secretary of Health and Human Services. 

Mr. Abdoo received a Bachelor of Arts degree from College of the Holy Cross and conducted graduate studies at Brown University. Before entering joining Federal service, he lived in East Asia for nine years, where he owned two consulting companies. He is fluent in Mandarin.

Deputy Director, Office of Global Policy and Strategy

Ravi Bharwani

Ravi Bharwani, principal advisor for global policy in the Office of Global Policy and Strategy (OGPS), has been promoted to OGPS Deputy Director. As principal policy advisor in the OGPS immediate office (IO) since 2021, Bharwani led stakeholder or counterpart engagements and coordination, advised the associate commissioner on complex issues, and managed IO functions – including budget formulation and oversight, the OGPS ORISE program, and cross-cutting policy initiatives. 

Bharwani started his FDA career as a student intern in 2007 with the Office of Resource Management, part of what was then the Office of Regulatory Affairs (ORA). Upon graduating from American University with a degree in public policy, he was selected as the first employee to join the new ORA Quality Management Staff. In this position, he performed quantitative and qualitative analysis and helped establish the new program while working toward graduate degrees in business administration and finance from the University of Maryland, College Park. 

In 2013, Bharwani joined the newly formed Office of Public Health and Trade in what was then the Office of International Programs (OIP) as an international trade policy analyst. His work focused on OIP’s World Trade Organization (WTO) portfolio and policy positions with the Technical Barriers to Trade and Good Regulatory Practices interagency groups within the WTO.

He joined the Global Regulatory Operations and Policy Directorate (GO) in 2017 as a policy advisor where he negotiated FDA equities in the United States-Mexico Canada Agreement, managed the GO/IO budget, and coordinated policy issues with HHS and trade-promoting agencies. Since OGPS’s inception, he has worked on managing the office’s budget, preparing positions for Congressional and HHS stakeholders, and advancing policy coherence across OGPS.

Back to Top